Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of -11.02% and Operating profit at -12.36% over the last 5 years
2
With a fall in Net Sales of -3.45%, the company declared Very Negative results in Mar 25
3
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 2,435 Million (Small Cap)
17.00
NA
2.12%
-0.30
4.74%
0.82
Revenue and Profits:
Net Sales:
357 Million
(Quarterly Results - Jun 2025)
Net Profit:
26 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-2.64%
0%
-2.64%
6 Months
-1.53%
0%
-1.53%
1 Year
-11.49%
0%
-11.49%
2 Years
-16.03%
0%
-16.03%
3 Years
-21.88%
0%
-21.88%
4 Years
-52.29%
0%
-52.29%
5 Years
-51.91%
0%
-51.91%
MedicalSystem Biotechnology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-11.02%
EBIT Growth (5y)
-12.36%
EBIT to Interest (avg)
24.44
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.25
Sales to Capital Employed (avg)
0.65
Tax Ratio
6.81%
Dividend Payout Ratio
20.02%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
9.78%
ROE (avg)
8.27%
Valuation key factors
Factor
Value
P/E Ratio
17
Industry P/E
Price to Book Value
0.82
EV to EBIT
19.99
EV to EBITDA
5.04
EV to Capital Employed
0.75
EV to Sales
1.03
PEG Ratio
NA
Dividend Yield
2.12%
ROCE (Latest)
3.75%
ROE (Latest)
4.74%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
357.10
369.90
-3.46%
Operating Profit (PBDIT) excl Other Income
47.80
71.40
-33.05%
Interest
0.00
0.40
-100.00%
Exceptional Items
-0.40
0.60
-166.67%
Consolidate Net Profit
25.80
29.80
-13.42%
Operating Profit Margin (Excl OI)
1.40%
65.10%
-6.37%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -3.46% vs 10.88% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -13.42% vs -24.17% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,727.10
1,866.70
-7.48%
Operating Profit (PBDIT) excl Other Income
455.90
437.50
4.21%
Interest
2.70
10.90
-75.23%
Exceptional Items
-13.30
-14.50
8.28%
Consolidate Net Profit
262.70
259.50
1.23%
Operating Profit Margin (Excl OI)
134.90%
135.40%
-0.05%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -7.48% vs -24.54% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 1.23% vs 26.46% in Dec 2023
About MedicalSystem Biotechnology Co., Ltd. 
MedicalSystem Biotechnology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






